孟鲁司特对人鼻黏膜上皮细胞黏蛋白MUC2和MUC5B mRNA表达的影响

目的 探讨白三烯受体拮抗剂孟鲁司特对人鼻黏膜上皮细胞黏蛋白MUC2和MUC5BmRNA表达的影响。方法 应用下鼻甲黏膜组织进行鼻黏膜上皮细胞的原代培养，取第2代培养的鼻黏膜上皮细胞分成对照组、IL-1β组、孟鲁司特+IL-1β组和孟鲁司特组。IL-1β组加入含IL-1β(10 μg/L)的无血清培养基；孟鲁司特+IL-1β组先加入孟鲁司特(0.01 mol/L)孵育8h后，再加入含IL-1β（10μg/L）的无血清培养基；孟鲁司特组加入含孟鲁司特(0.01 mol/L)的无血清培养基；对照组仅加入无血清培养基。培养24h后通过荧光定量PCR检测各组上皮细胞黏蛋白MUC2和MUC5B mRNA的表达。结果对照组MUC2和MUC5B mRNA和孟鲁司特组水平相近MUC2:(2.93±1.57)×106拷贝/μg、( 1.63±0.47)× 106拷贝/μg;M UC5B:(8.21±3.54)×105拷贝/μg(5.15±2.16)×105拷贝/μg]。而孟鲁司特+IL-1β组MUC2和MUC5B mRNA定量表达均低于IL-1β组(3.48±1.41)× 106拷贝/μg比(6.63±1.73)× 10拷贝/μg，MUC5B：(1.75±0.69)×106拷贝/μg比(3.40±2.79)×107拷贝/μg，均P＜0.05]，但高于对照组和孟鲁司特组（均P＜0.05）。结论 孟鲁司特可降低IL-1β诱导的鼻黏膜上皮细胞黏蛋白MUC2和MUC5BmRNA的表达，但不影响正常状态鼻黏膜上皮细胞黏蛋白mRNA的表达，可能对炎性细胞因子诱导的鼻黏膜上皮细胞黏蛋白mRNA的表达有抑制作用。

Effects of montelukast on MUC2 and MUC5B musins mRNA expression in cultured human nasal epithelial cells

Objective To evaluate the effects of montelukast, a leukotriene receptor antagonist (LTRA) on MUC2 and MUC5B musins mRNA expression in cultured human nasal epithelial cells.Methods Primary culture of human nasal epithelial cells (HNECs) was performed using inferior turbinate mucosa. The second-passage of HNECs were randomized to the control group, IL-1β group, montelukast plus IL-1β group and montelukast group. The IL-1β group was added with 10 μg/L IL-1β containing PBS-free culture medium. The montelukast plus IL- 1β group treated with 0.01mol/L montelukast for 8 h and then added with 10 μg/L IL- 1β-containing PBS-free culture medium. The montelukast group added with 0.01 mol/L montelukast-containing PBS-free culture medium, and the control group added with PBS-free culture medium alone. After incubation for 24 h, the expressions of MUC2 and MUC5B musins mRNA were detected by fluorescent quantitative RT-PCR in each group. Results The levels of MUC2 and MUC5B expression in HNECs were similar between the control group and the montelukast groupMUC2: (2.93± 1.57)× 106copies/μg vs ( 1.63 ±0.47) ×106 copies/μg; MUC5B: (8.21 ± 3.54) × 105 copies/μg vs (5.15± 2.16) × 105copies/μg]. The levels of MUC2 and MUC5B expression in montelukast plus IL-1β group were significantly lower compared with IL- 1β groupMUC2: (3.48± 1.41 ) × 106 copies/μg vs (6.63± 1.73) × 106 copies/μg,MUC5B: (1.75±0.69)× 106 copies/μg vs (3.40±2.79)× 107 copies/μg, all P＜0.05], but significantly higher compared with the control group and the montelukast group. Conclusion Montelukast can down-regulate MUC2 and MUC5B musins mRNA expression in human nasal epithelial cells induced by IL-1β but not in those under normal conditions, which may have an inhibitory action against inflammatory cytokine-induced mucin mRNA expression in HNECs.